Robert Marcus
Stock Analyst at JP Morgan
(2.16)
# 2,606
Out of 4,789 analysts
31
Total ratings
52.38%
Success rate
4.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Overweight | $230 → $285 | $267.41 | +6.58% | 3 | Feb 19, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $21.99 | +241.06% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $229.06 | +15.69% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $98.42 | -49.20% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $67.28 | -77.71% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $32.26 | +76.69% | 2 | Jul 29, 2020 | |
| NVRO Nevro | Maintains: Neutral | $90 → $100 | $5.84 | +1,612.33% | 10 | May 6, 2020 |
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $230 → $285
Current: $267.41
Upside: +6.58%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $21.99
Upside: +241.06%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $229.06
Upside: +15.69%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $98.42
Upside: -49.20%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $67.28
Upside: -77.71%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $32.26
Upside: +76.69%
Nevro
May 6, 2020
Maintains: Neutral
Price Target: $90 → $100
Current: $5.84
Upside: +1,612.33%